Ardent Health, Inc. $ARDT Shares Sold by CastleKnight Management LP

CastleKnight Management LP decreased its position in shares of Ardent Health, Inc. (NYSE:ARDT) by 32.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,167,947 shares of the company’s stock after selling 570,969 shares during the period. CastleKnight Management LP’s holdings in Ardent Health were worth $10,313,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. Geode Capital Management LLC lifted its stake in Ardent Health by 0.6% during the 2nd quarter. Geode Capital Management LLC now owns 286,848 shares of the company’s stock worth $3,918,000 after acquiring an additional 1,769 shares in the last quarter. The Manufacturers Life Insurance Company lifted its stake in Ardent Health by 8.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 27,530 shares of the company’s stock worth $376,000 after acquiring an additional 2,110 shares in the last quarter. Caitong International Asset Management Co. Ltd lifted its stake in Ardent Health by 1,177.7% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 2,862 shares of the company’s stock worth $25,000 after acquiring an additional 2,638 shares in the last quarter. Alliancebernstein L.P. lifted its stake in Ardent Health by 24.8% during the 3rd quarter. Alliancebernstein L.P. now owns 16,472 shares of the company’s stock worth $218,000 after acquiring an additional 3,272 shares in the last quarter. Finally, New York State Common Retirement Fund lifted its stake in Ardent Health by 121.4% during the 2nd quarter. New York State Common Retirement Fund now owns 6,200 shares of the company’s stock worth $85,000 after acquiring an additional 3,400 shares in the last quarter.

Insider Buying and Selling

In other Ardent Health news, CFO Alfred Lumsdaine purchased 10,000 shares of the firm’s stock in a transaction that occurred on Friday, June 5th. The stock was purchased at an average price of $8.81 per share, for a total transaction of $88,100.00. Following the purchase, the chief financial officer directly owned 329,183 shares in the company, valued at approximately $2,900,102.23. This trade represents a 3.13% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 1.90% of the stock is currently owned by company insiders.

Ardent Health Trading Down 1.7%

NYSE:ARDT opened at $9.11 on Thursday. The stock’s 50 day moving average price is $9.51 and its 200 day moving average price is $9.13. The company has a market capitalization of $1.31 billion, a PE ratio of 9.58, a P/E/G ratio of 2.10 and a beta of 0.84. The company has a quick ratio of 2.00, a current ratio of 2.12 and a debt-to-equity ratio of 0.62. Ardent Health, Inc. has a 52-week low of $7.71 and a 52-week high of $15.48.

Ardent Health (NYSE:ARDT) last released its quarterly earnings results on Tuesday, May 5th. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.18 by $0.10. The firm had revenue of $1.60 billion for the quarter, compared to the consensus estimate of $1.58 billion. Ardent Health had a return on equity of 13.85% and a net margin of 2.09%.Ardent Health has set its FY 2026 guidance at 0.900-1.270 EPS. On average, research analysts anticipate that Ardent Health, Inc. will post 1.11 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. Leerink Partners reduced their price target on Ardent Health from $16.00 to $15.00 and set an “outperform” rating on the stock in a research report on Friday, March 6th. Weiss Ratings reissued a “sell (d+)” rating on shares of Ardent Health in a research report on Friday, June 12th. Zacks Research raised Ardent Health from a “strong sell” rating to a “hold” rating in a research report on Wednesday, March 25th. Wall Street Zen raised Ardent Health from a “hold” rating to a “buy” rating in a research report on Saturday, May 16th. Finally, UBS Group raised their target price on Ardent Health from $13.00 to $13.50 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Seven analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Ardent Health has a consensus rating of “Hold” and a consensus price target of $14.21.

About Ardent Health

Ardent Health, listed on the New York Stock Exchange under the ticker ARDT, is a healthcare delivery company focused on acquiring, developing and managing acute care hospitals and complementary outpatient facilities across the United States. The company’s integrated platform encompasses both inpatient and outpatient services, designed to provide end-to-end care solutions and address the full continuum of patient needs.

Through its network, Ardent Health operates general hospitals, emergency departments, ambulatory surgery centers, urgent care clinics, rehabilitation and post-acute care facilities.